Table 1

Patient characteristics and response.

N, %	Danazol users	Danazol non-users	P
N	8	8	NA
Age at ITP diagnosis, years (median, range)	53 (22–75)	61 (37–84)	0.374
Sex, female	7 (87.5)	8 (100)	1.000
Duration of ITP at romiplostim start, years (median, range)	7 (2–17)	7 (4–28)	0.430
N of prior treatments (median, range)	4 (3–7)	5 (3–7)	0.355
Prior treatments
IVIG/Anti-D	8 (100)	8 (100)	NA
Splenectomy	5 (62.5)	7 (87.5)	0.569
Rituximab	1 (12.5)	4 (50.0)	0.282
Immunosuppressants	2 (25.0)	3 (37.5)	1.000
Corticosteroids	8 (100)	8 (100)	NA
Danazol	5 (62.5)	3 (37.5)	0.619
Eltrombopag	8 (100)	8 (100)	NA
Baseline platelet count, ×10⁹/L (mean, range)	10.3 (4–21)	7.9 (4–17)	0.362
Best response
Complete response	8 (100)	6 (75)	0.467^a)
Partial response	0	1 (12.5)	0.302^b)
No response	0	1 (12.5)
Loss of response	2/8 (25.0)	3/7 (42.9)
Time to best response, weeks (median, range)	11 (2–22)	13 (3–42)	0.423

^a)P-value for complete response rates. ^b)P-value for partial response or better (i.e. partial response+complete response) rates.

Abbreviations: ITP, idiopathic thrombocytopenic purpura; IVIG, intravenous immunoglobulin; NA, not applicable.